Email updates

Keep up to date with the latest news and content from BMC Immunology and BioMed Central.

Open Access Research article

Significance of decoy receptor 3 (Dcr3) and external-signal regulated kinase 1/2 (Erk1/2) in gastric cancer

Donghai Yang12, Xin Fan1, Ping Yin1, Qiang Wen1, Feng Yan1, Sibo Yuan2, Bin Liu1, Guohong Zhuang1* and Zhongchen Liu2*

Author Affiliations

1 Anti-Cancer Research Center, Medical College, Xiamen University, Xiamen, China

2 Zhongshan Hospital, Xiamen University, Xiamen, China

For all author emails, please log on.

BMC Immunology 2012, 13:28  doi:10.1186/1471-2172-13-28

Published: 6 June 2012



Decoy receptor 3 (DcR3), a member of the tumor necrosis factor receptor (TNFR) superfamily, is associated with anti-tumor immunity suppression. It is highly expressed in many tumors, and its expression can be regulated by the MAPK/MEK/ERK signaling pathway. The MAPK/MEK/ERK pathway has been reported to be a regulator in tumor occurrence, development and clonal expansion. External-signal regulated kinase (ERK) is a vital member of this pathway.


The expression of DcR3 and ERK1/2 in tumor tissues of gastric cancer patients was significantly higher than the non-cancerous group (P < 0.05). There was no statistical difference among tumor tissues from patients with different ages or gender, and even of different differentiation (P > 0.05). However, in patients with stage I gastric cancer, the DcR3 and ERK1/2 levels were significantly lower than patients with more advanced stages.


DcR3 and ERK1/2 play a vital role in the development of gastric cancer, and they may be new markers for indicating the efficiency of gastric cancer treatment in the future.